Federated Investors Inc. PA lowered its holdings in NuVasive, Inc. (NASDAQ:NUVA) by 26.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,684 shares of the medical device company’s stock after selling 8,702 shares during the period. Federated Investors Inc. PA’s holdings in NuVasive were worth $1,822,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. State Board of Administration of Florida Retirement System grew its position in shares of NuVasive by 3.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 32,600 shares of the medical device company’s stock valued at $2,508,000 after purchasing an additional 1,129 shares during the period. Redwood Investments LLC grew its position in shares of NuVasive by 15.9% in the second quarter. Redwood Investments LLC now owns 86,422 shares of the medical device company’s stock valued at $6,648,000 after purchasing an additional 11,870 shares during the period. Blair William & Co. IL grew its position in shares of NuVasive by 1.6% in the second quarter. Blair William & Co. IL now owns 275,927 shares of the medical device company’s stock valued at $21,224,000 after purchasing an additional 4,332 shares during the period. Chartwell Investment Partners LLC grew its position in shares of NuVasive by 40.9% in the second quarter. Chartwell Investment Partners LLC now owns 45,973 shares of the medical device company’s stock valued at $3,536,000 after purchasing an additional 13,353 shares during the period. Finally, BNP Paribas Arbitrage SA grew its position in shares of NuVasive by 120.0% in the second quarter. BNP Paribas Arbitrage SA now owns 26,446 shares of the medical device company’s stock valued at $2,034,000 after purchasing an additional 14,427 shares during the period.

In other NuVasive news, CEO Gregory T. Lucier bought 5,000 shares of the stock in a transaction on Thursday, August 17th. The shares were purchased at an average cost of $66.22 per share, with a total value of $331,100.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Gregory T. Lucier bought 2,000 shares of the stock in a transaction on Tuesday, August 29th. The shares were acquired at an average cost of $61.52 per share, for a total transaction of $123,040.00. The disclosure for this purchase can be found here. Insiders have acquired 14,850 shares of company stock worth $955,598 over the last three months. Company insiders own 1.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/09/11/nuvasive-inc-nuva-stake-lowered-by-federated-investors-inc-pa.html.

A number of equities research analysts have recently commented on NUVA shares. Cowen and Company reaffirmed an “outperform” rating and issued a $90.00 price objective (up previously from $85.00) on shares of NuVasive in a research report on Wednesday, June 28th. Robert W. Baird downgraded NuVasive from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $79.00 to $72.00 in a research report on Friday, July 28th. Gabelli reissued a “buy” rating on shares of NuVasive in a research report on Monday, July 31st. Royal Bank Of Canada reissued a “buy” rating and set a $85.00 price target on shares of NuVasive in a research report on Thursday, July 20th. Finally, Zacks Investment Research downgraded NuVasive from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $80.42.

NuVasive, Inc. (NUVA) opened at 61.40 on Monday. NuVasive, Inc. has a 52 week low of $56.70 and a 52 week high of $81.68. The firm’s 50 day moving average price is $66.12 and its 200-day moving average price is $72.86. The firm has a market cap of $3.12 billion, a PE ratio of 96.69 and a beta of 1.08.

NuVasive (NASDAQ:NUVA) last posted its earnings results on Thursday, July 27th. The medical device company reported $0.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.02. The firm had revenue of $260.60 million for the quarter, compared to the consensus estimate of $261.95 million. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.40 earnings per share. On average, analysts forecast that NuVasive, Inc. will post $2.00 EPS for the current year.

NuVasive Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA).

Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Stock Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related stocks with our FREE daily email newsletter.